# Safety of F14 Following Total Knee Replacement

> **NCT04860635** · PHASE2,PHASE3 · SUSPENDED · sponsor: **Arthritis Innovation Corporation** · enrollment: 100 (estimated)

## Conditions studied

- Analgesia

## Interventions

- **DRUG:** F14 (sustained release celecoxib)

## Key facts

- **NCT ID:** NCT04860635
- **Lead sponsor:** Arthritis Innovation Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-09
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Study superseded by alternative Phase 3 trial
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04860635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04860635, "Safety of F14 Following Total Knee Replacement". Retrieved via AI Analytics 2026-07-22 from https://api.ai-analytics.org/clinical/NCT04860635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*